Growth Strategy: Evidence-Based Reimbursement and Commercialization Strategies for Innovators and Investors
2010년 9월 29일
In today’s rigorous health care environment new products must present a high profit and value proposition to potential investors and acquirers. Along with this increased level of scrutiny, payers are reviewing comparative effectiveness data and more carefully examining economic data for reimbursements. In this session panelists will discuss:
Medicare product coverage strategy
Proper planning for product pricing
Preparing comparative effectiveness data
Working with payer expectations
Data that should be in place for partnering or acquisition deals
패널리스트:
Judith A. Waltz, Partner, Foley & Lardner LLP
Anita Chawla, Ph.D., Vice President, Analysis Group
관련 인사이트
December 19, 2025
Health Care Law Today
Gender Affirming Care for Minors: CMS and HHS Propose Limits on “Sex Rejection Procedures” and Expanded Enforcement Pathways
On December 18, 2025, the U.S. Department of Health and Human Services (HHS) held a press conference focused on what is defined as “sex…
December 19, 2025
Foley Viewpoints
Prohibition to Prescription: What Trump’s Marijuana Executive Order Really Means
On December 18, 2025, President Donald Trump issued an Executive Order, Increasing Medical Marijuana and Cannabidiol Research, that…
2025년 12월 18일
제조업 고문
폴리 자동차 업데이트
줄리 도터만, 경쟁 정보 분석가의 분석 폴리는 장기적인 전략 재구상의 모든 측면을 지원하기 위해 여기 있습니다…